Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Korsana Biosciences, Inc.CYCN · Entity 7698 | Director · See Remarks | August 14, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Korsana Biosciences, Inc.
Report date August 14, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, no par valueSEC Table I · non-derivative | Direct | 107,523 |
Ending reported balance
After 2026-08-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-14 · Exercise / conversion · Acquired 55,849 · Balance 156,152 F1: The Reporting Person was granted an option on August 5, 2024 to purchase up to 55,849 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan, vesting ratably in monthly installments over a 48-month period commencing August 31, 2024 and ending July 31, 2028, provided that the Reporting Person remained employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options and all then unvested restricted shares for the Reporting Person. Row 2 · 2026-08-14 · Tax withholding · Disposed 48,629 · Balance 107,523 F2: The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cashless exercise, forfeiting options to purchase 48,629 shares as payment to the Issuer for the full exercise price. |
| Option to PurchaseSEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2034-08-03 | Direct | 0 |
Reported balance
After 2026-08-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-14 · Exercise / conversion · Disposed 55,849 · Balance 0 F1: The Reporting Person was granted an option on August 5, 2024 to purchase up to 55,849 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan, vesting ratably in monthly installments over a 48-month period commencing August 31, 2024 and ending July 31, 2028, provided that the Reporting Person remained employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options and all then unvested restricted shares for the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted an option on August 5, 2024 to purchase up to 55,849 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan, vesting ratably in monthly installments over a 48-month period commencing August 31, 2024 and ending July 31, 2028, provided that the Reporting Person remained employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options and all then unvested restricted shares for the Reporting Person.
F2: The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cashless exercise, forfeiting options to purchase 48,629 shares as payment to the Issuer for the full exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 18, 2026 21:21 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | Exercise / conversionOption to Purchase · Derivative | 55,849 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001193125-26-355707 · ownership.xml · derivative · entry 3 Graul Regina Margaret · CIK 0002002981 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,849 shares Expires 2034-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person was granted an option on August 5, 2024 to purchase up to 55,849 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan, vesting ratably in monthly installments over a 48-month period commencing August 31, 2024 and ending July 31, 2028, provided that the Reporting Person remained employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options and all then unvested restricted shares for the Reporting Person. F1 · derivative.exercise_date: The Reporting Person was granted an option on August 5, 2024 to purchase up to 55,849 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan, vesting ratably in monthly installments over a 48-month period commencing August 31, 2024 and ending July 31, 2028, provided that the Reporting Person remained employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options and all then unvested restricted shares for the Reporting Person. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 21:21 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | Tax withholdingCommon Stock, no par value | 48,629 | $3.79 | $184,303.91 |
DisclosureSEC source: 0001193125-26-355707 · ownership.xml · nonDerivative · entry 2 Graul Regina Margaret · CIK 0002002981 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,523 F2 · kind: The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cashless exercise, forfeiting options to purchase 48,629 shares as payment to the Issuer for the full exercise price. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 21:21 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | Exercise / conversionCommon Stock, no par value | 55,849 | $3.30 | $184,301.70 |
DisclosureSEC source: 0001193125-26-355707 · ownership.xml · nonDerivative · entry 1 Graul Regina Margaret · CIK 0002002981 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person was granted an option on August 5, 2024 to purchase up to 55,849 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan, vesting ratably in monthly installments over a 48-month period commencing August 31, 2024 and ending July 31, 2028, provided that the Reporting Person remained employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options and all then unvested restricted shares for the Reporting Person. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 20:05 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantStock Option (Right to Buy) · Derivative | 55,849 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0000950170-24-092733 · ownership.xml · derivative · entry 1 Graul Regina Margaret · CIK 0002002981 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,849 Underlying: Common Stock · 55,849 shares Expires 2034-08-05 F1 · derivative.exercise_date: The Reporting Person was granted an option to purchase up to 55,849 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan. These 55,849 shares vest ratably in monthly installments over a 48-month period commencing August 31, 2024 and ending July 31, 2028, provided that the Reporting Person remains employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. Read SEC document |
| January 01, 2024 Filed Jan 26, 2024 21:05 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-007917 · ownership.xml · nonDerivative · entry 1 Graul Regina Margaret · CIK 0002002981 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,303 F1 · shares: The Reporting Person was granted 50,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 10,000 of the shares vest immediately and the remaining 40,000 shares are subject to vesting ratably over a 48-month period, provided that the Reporting Person remains employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.